“There isn’t much data on Delta plus variant to suggest it’s more infectious, causing more deaths, or has developed significant immune escape mechanism. But if we follow COVID appropriate behaviour and get vaccinated, we’ll be safe against any of emerging variants,” Dr Guleria told ANI.

“The Subject Expert Committee (SEC) recommended that the Pune-based company should submit the safety and immunogenicity data of Covavax from the ongoing trials in adults for considering the trials in children,” sources told ANI.